What does pazopanib/pazopanib treat?

Pazopanib/Pazopanib is a multikinase inhibitor that targets the angiogenesis process by inhibiting multiple important enzymes, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-KIT, and plasminogen kinase receptor (FGFR). These enzymes play a key role in regulating angiogenesis, and by inhibiting their function, pazopanib limits tumor growth. Pazopanib is currently widely used in the treatment of two types of cancer:

1. Renal cell carcinoma (RCC): Pazopanib has been proven to be an effective treatment for adult patients with advanced renal cell carcinoma. It can help control the growth and spread of tumors and improve patient survival rates.

2. Soft tissue sarcoma (STS): This is a tumor that can develop in or around muscles, tendons, joints, organs, or blood vessels. Pazopanib also showed modest efficacy in adults with advanced soft tissue sarcoma who had previously received chemotherapy. It can slow down the progression of the disease and improve patients' quality of life.

Pazopanib is usually used after other treatments have failed. It should be noted that there are still certain restrictions on the use of pazopanib. Efficacy has not yet been demonstrated in the treatment of adipocyte-derived soft tissue sarcomas or gastrointestinal stromal tumors (GIST), so use in these settings requires more research and clinical validation.

Although pazopanib is effective in treating the disease, the drug also has certain side effects. Common side effects are nausea, vomiting, diarrhea, hair color change, high blood pressure, loss of appetite, hyperglycemia, hypoglycemia, etc. Therefore, the drug should be used under the guidance of a doctor.